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Abstract
Background: Alzheimer’s disease (AD) is a progressively developing neurodegenerative disorder of the brain in
the elderly people. Vanda roxburghii Rbr. root has been used traditionally in Bangladesh as tonic to brain and
in the treatment of nervous system disorders including AD. Therefore, we aimed to investigate the cholinesterase
inhibitory activities and antioxidant properties of the extracts from V. roxburghii.
Methods: The crude methanol extract from the roots of plant was sequentially fractionated with petroleum ether,
chloroform, ethylacetate and water to yield their corresponding extracts. The extracts were assessed for
acetylcholinesterase and butyrylcholinesterase inhibitory activity by modified Ellman method and antioxidant
property by several assays including ferric reducing antioxidant power, scavenging of 1,1-diphenyl-2-picrylhydrazyl
(DPPH) free radical and hydroxyl radical, and inhibition of lipid peroxidation. Endogenous substances in the extracts
were analyzed by the standard phytochemical methods and active compound was isolated by the chromatographic
methods.
Results: Chloroform extract was shown to demonstrate strong ferric-reducing antioxidant power and scavenging
activity against DPPH and hydroxyl free radicals when compared with the other extracts and the reference standard
catechin. The antioxidant effect was further verified by inhibition of lipid peroxidation in rat brain homogenates. Likewise,
the chloroform extract exhibited the highest inhibition against both the acetylcholinesterase and butyrylcholinesterase
enzymes with IC50 values of 221.13 and 82.51 μg/ml, respectively. Phytochemical screening revealed a large amount
of phenolics and flavonoids in the chloroform extract. Bioactivity guided separation techniques led to the isolation of
a strong antioxidant from the chloroform extract and its structure was determined as gigantol on the basis of
spectral studies.
Conclusion: These results suggest that the chloroform extract of V. roxburghii, possibly due to its phenolic compounds,
exert potential antioxidant and cholinesterase inhibitory activities, which may be useful in the treatment of AD.
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Background
Alzheimer’s disease (AD) is the most prevalent neurode-
generative disorder in the elderly people with symptoms
of memory loss, cognition and behavioral abnormalities.
The major neuropathological characteristics observed in
AD are senile plaque consisting of Abeta protein, and
neurofibrillary tangles of microtubule associated protein
tau, and loss of cholinergic neurons [1–4]. Currently
there is no definitive treatment or cure for this disease.
Extensive biochemical studies with AD revealed cholinergic
dysfunction and oxidative stress as the major contributing
factors in the pathogenesis [4, 5]. It is well established that
the cholinergic system, which is responsible for the storage
and retrieval of items in memory, is impaired in AD [6, 7].
The reduced cholinergic transmission and the associated
decrease of acetylcholine (ACh) have been shown to be
critical in the development of dementia [8]. Therefore,
inhibition of acetylcholinesterase (AChE) as well as
butyrylcholinesterase (BChE), which are involved in
the breakdown of acetylcholine, has been the main
strategy followed for the treatment of AD [9, 10].
Until now, only three cholinesterase inhibitors (ChEI)
such as donepezil, galantamine and rivastigmine has
been approved by the US Food and Drug Administration
(FDA) to treat AD [11, 12]. These drugs are effective only
in mild to moderate AD and do not reverse the disease
progression. Moreover, they are associated with multiple
side effects [13]. Therefore, it has become a necessity to
develop the new ChE inhibitors that are pharmacologically
safe, cost effective and immediately available with minimal
side effects.
Oxidative stress (OS) has been shown to be another
important factor in the pathological cascade of AD.
Oxidative stress markers including lipid peroxidation,
modification of DNA, protein oxidation and reactive
oxygen species (ROS) formation has been documented
in the brains of AD [14–16]. Numerous studies suggested
that oxidative stress and amyloid A-beta protein are linked
each other because amyloid A-beta induces oxidative
stress in vivo and in vitro [14, 15], and oxidative stress
increases the production of amyloid A-beta [16, 17].
Oxidative stress increases is believed to be an early event
in AD pathology [18, 19] as it contributes to membrane
damage, cytoskeleton alterations and cell death [20].
Therefore, antioxidant therapies have been suggested
as a potential means to reduce reactive oxygen species
(ROS)-based damage in AD [21, 22]. Plants rich in poly-
phenol and flavonoids are important sources of antioxi-
dants and have shown effective in oxidative damage of
tissue [23].
Vanda roxburghii, belonging to the family Orchidaceae, is
an epiphyte and widely distributed throughout Bangladesh.
Medicinal uses of this plant have been described well in
both Unani and Ayurveic systems of medicine [24–26]. In
Yunani medicine, the root is used as tonic to the liver and
brain and also indicated in the treatment of bronchitis,
piles, lumbago, toothache, boils of the scalp and fractures
[24]. The plant is traditionally used by the local people of
Bangladesh to treat diseases of nervous system including
AD [25]. According to ethnomedical uses, the root of plant
is reputed to have activity against inflammations,
bronchitis, rheumatic pain, disease of abdomen, tremor
and infectious diseases including bacterial infections and
tuberculosis. The leaves are pounded and the paste is
applied to the body to bring down fever; their juice is
dropped in the ear for the treatment of otitis and other
inflammatory conditions [26]. A comprehensive review of
literature revealed that the plants of this family has some
promising biological activities like antiinflammatory,
antiarthritic, antimicrobial, anticancer, antioxidant, antino-
ciceptive, and wound healing properties [27–33]. Previously
we reported the antibacterial activity of the methanol
extract of V. roxburghii [33]. Given the ethnomedicinal uses
of this plant in the nervous system disorders, we have
undertaken to evaluate the cholinesterase inhibitory activity
and antioxidant property of the extracts from V. roxburghii.
Methods
Chemicals
DPPH (1, 1′-diphenyl-2-picrylhydrazyl), aluminum chloride,
ammonium molybdate, potassium ferricyanide, ascorbic
acid, Folin-ciocalteu reagent, Tris–HCl and triton X-100
were obtained from Sigma-Aldrich, India. Gallic acid was
obtained from Wako Pure Chemical Company Ltd., Japan.
2-deoxy-D-ribose, 2-thiobarbituric acid (TBA), catechin,
quercetin, 5,5′-dithio-bis-(2-nitro) benzoic acid (DTNB),
acetylthiocholine iodide, S-butyrylthiocholine, galantamine,
and donepezil were obtained from Sigma-Aldrich, Japan.
Unless otherwise specified, all other chemicals were of
analytical grade.
Plant material
The roots of V. roxburghii were collected from Rajshahi
University campus, Rajshahi, Bangladesh, and identified
by an expert taxonomist. A voucher specimen (collection
no. 92) was submitted to the herbarium of the Department
of Botany, Rajshahi University.
Extraction
Fresh roots of V. roxburghii were thoroughly washed,
crushed into small pieces, shade-dried and ground into
coarse powder by using grinding mill. Dried powder
(500 g) was extracted with methanol for 7 days at
room temperature with occasional shaking and stirring.
The extract was then filtered and concentrated with a
rotary evaporator under reduced pressure at 50 °C
temperature to afford the crude methanol extract
(12.5 g). An aliquot (10 g) of the concentrated methanolic
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extract was partitioned by the method as described earlier
[34] and the resultant partitionates that is petroleum ether
(PEF, 2.05 g), chloroform (CLF, 3.68 g), ethylacetate (EAF,
1.67 g) and aqueous (AQF, 2.6 g) extracts were obtained
and used for the experiment purpose.
Phytochemical screening of the plant extract
Preliminary qualitative analysis of the extracts were carried
out to determine the presence of various phytochemicals
which include tannins, phenolics and flavonoids, alkaloids,
saponins, and steroids in accordance with the methods as
described [34].
Determination of total phenolic content (TPC)
The TPC of the different extracts of V. roxburghii was
determined using the Folin-Ciocalteu reagent [35]. 0.5 ml
of plant extract or standard solution at different concentra-
tions was added to 2.5 ml of Folin – ciocalteu (diluted 10
times with water) reagent and 2.5 ml of sodium carbonate
(7.5 %) solution. The reaction mixture was incubated
for 20 min at 25 °C to complete the reaction and the
absorbance of the mixture was measured at 760 nm.
Gallic acid was used as standard and the results were
expressed as mg of gallic acid equivalent (GAE)/g of
dried extract.
Determination of total flavonoid content (TFC)
The TFC of the different extracts of V. roxburghii was
determined by aluminum chloride colorimetric method
using catechin as a standard [36]. The plant extract
(1.0 ml) was added to 3.0 ml of methanol, 0.2 ml of 10 %
AlCl3, 0.2 ml of 1 M potassium acetate and 5.6 ml of
distilled water. The reaction mixture was then incubated
at room temperature for 30 min to complete the reac-
tion. The absorbance of the mixture was measured at
420 nm. Catechin was used as standard and the results
were expressed as mg of catechin equivalent (CE)/g of
dried extract.
Determination of ferric reducing antioxidant power
(FRAP)
The FRAP of different extracts of V. roxburghii was
evaluated by the method of Oyaizu [37]. Plant extract or
standard solutions at different concentration (1 ml) were
mixed with 2.5 ml each of potassium phosphate buffer
(0.2 M) and potassium ferricyanide (1 % w/v). The
resulting mixture was incubated at 50 °C for 20 min
followed by addition of 2.5 ml of trichloro acetic acid
(10 % w/v) solution. The mixture was centrifuged at
3000 rpm for 10 min to collect the upper layer. 2.5 ml of
solution from upper layer was mixed with 2.5 ml of distilled
water and 0.5 ml of ferric chloride (0.1 % w/v) solution.
The absorbance of the solution was then measured at
700 nm. Catechin was used for comparison.
Determination of DPPH radical scavenging activity
DPPH radical scavenging activity of the different extracts
of V. roxburghii was determined according to the method
described by Choi et al. [38] with slight modifications. 2 ml
of methanol solution of plant extract or reference standard
at different concentration was mixed with 3 ml of metha-
nol solution of DPPH (0.135 mM) into the test tube. The
reaction mixture was incubated at room temperature for
30 min in dark place to complete the reaction. The absorb-
ance of the solution was measured spectrophotometrically
at 517 nm. DPPH free radical scavenging ability (%) was
calculated by using the formula:
Aabsorbance of control– Aabsorbance of sample
 






\mathrm{of}\ \mathrm{control}}\right] \times 100$$
Determination of hydroxyl radical scavenging activity
The activity of the different V. roxburghii extracts in the
scavenging of hydroxyl free radical was determined by the
method as described by Elizabeth et al. [39] with a slight
modification. In brief, plant extract or reference compound
at different concentration was mixed with a reaction mix-
ture contained, in a final volume of 1 ml: 2-deoxy-2-ribose
(2.8 mM); KH2PO4-KOH buffer (20 mM, pH 7.4); FeCl3
(100 μM); EDTA (100 μM); H2O2 (1.0 mM); and ascorbic
acid (100 μM). The mixture was then incubated for 1 h at
37 °C and 0.5 ml of the reaction mixture was was heated at
90 °C for 15 min after addition of 1 ml of 2.8 % TCA
and 1 ml of 1 % aqueous TBA to develop the color. After
cooling, the absorbance was measured at 532 nm against
an appropriate blank solution. Hydroxyl radical scavenging
ability (%) was calculated by using the formula:
Aabsorbance of control– Aabsorbance of sample
 







\mathrm{of}\ \mathrm{control}}\right] \times 100$$
Determination of lipid peroxidation inhibition activity
The ability of the different extracts of V. roxburghii to
inhibit lipid peroxidation was determined according to
the method as described by Liu et al. [40] with a slight
modification. Rat brain was homogenized with a
homogenizer in ice-cold phosphate buffer (50 mM,
pH 7.4) with 0.15 M KCl to produce a 1/10 homogenate.
The homogenate was centrifuged at 10,000 g for 15 min
at 4 °C and the resulting supernatant was used as liposome
for in vitro lipid peroxidation assay. 1 ml of 0.15 M KCl
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and 0.5 ml of brain homogenates and different concentra-
tions of plant extract were mixed and the peroxidation
reaction was initiated by adding 100 ml of 0.2 mM ferric
chloride. After incubation at 37 °C for 30 min, the reaction
was stopped by adding 2 ml of ice-cold HCl (0.25 N) con-
taining 15 % trichloroacetic acid (TCA), 0.38 % TBA, and
0.5 % BHT. The reaction mixtures were heated at 80 °C for
60 min. The samples were cooled, centrifuged and the ab-
sorbance of the supernatants was measured at 532 nm.
The percentage of inhibition of lipid peroxidation was
calculated by the formula:
Aabsorbance of control– Aabsorbance of sample
 







\mathrm{of}\ \mathrm{control}}\right] \times 100$$
Determination of cholinesterase (ChE) inhibitory activities
The acetylcholinesterase (AChE) and butyrylcholinesterase
(BChE) inhibitory assay were performed according to the
colorimetric method of Ellman et al. [41]. For the
AChE enzyme source, rat brain was homogenized in a
homogenizer with 5 volumes of a homogenation buffer
[10 mM Tris–HCl (pH 7.2), which contained 1 M NaCl,
50 mM MgCl2 and 1 % Triton X-100], and centrifuged at
10,000 g for 30 min. The resulting supernatant was used as
an enzyme source. For the BChE enzyme source, human
blood from anonymous healthy men subject (25 years) was
provided by the Rajshahi Univresity Medical Center,
Rajshahi, Bagladesh and collected in EDTA treated
(1 mg/ml) glass tubes. The tubes were centrifuged at
2000 g for 10 min to eliminate the red blood cells. The
resulting plasma (supernatant) was then recuparated,
diluted (1/200) with 50 mM phosphate buffer (pH 7.4) and
was used immediately for studying butyrylcholinesterase
activity.
The rates of hydrolysis by acetylcholinesterase were
monitored spectrophotometrically. Each extract or standard
(500 μl) was mixed with an enzyme solution (200 μl) and
incubated at 37 °C for 15 min. Absorbance at 405 nm was
read immediately after adding an Ellman’s reaction mixture
[3.5 ml; 0.5 mM acetylthiocholine, 1 mM 5, 5′-dithio-bis
(2-nitro benzoic acid)] in a 50 mM sodium phosphate
buffer (pH 8.0) to the above reaction mixture. Reading
was repeated for 10 min at 2 min intervals to verify that
the reaction occurred linearly. The blank reaction was
measured by substituting saline for the enzyme. Donepezil
was used as positive control. The percentage inhibition of
acetylcholinesterase activity was calculated using the
following formula:
Aabsorbance of control– Aabsorbance of sample
 







\mathrm{of}\ \mathrm{control}}\right] \times 100$$Assessment of BChE inhibition was performed as
described above except that the enzyme solution was
50 μl and acetylthiocholine iodide (ACh) was replaced
by butyrylthiocholine iodide (BCh). Galantamine was
used as positive control. The percentage inhibition of
butyrylcholinesterase activity was calculated using the
same formula as mentioned above for acetylcholinesterase
activity.
Isolation of active compound from the chloroform extract
The chloroform extract (6.0 g) of V. roxburghii was
fractionated by silica gel 60 (Merck, Germany) column
chromatography using n-hexane, chloroform and methanol
gradient system with gradually increasing polarity.
Fractions of 25 ml were collected and concentrated.
All eluted fractions were monitored by thin layer
chromatography (TLC) and visualized under UV light
(254 nm). Fractions with antioxidant activity caused
by the same compounds (having the same Rf values)
were combined. A total of five fractions (CLC1, CLC2
CLC3, CLC4 and CLC5) were obtained. The most active
fraction CLC1 (1.1 g) was further separated by pre-
parative thin layer chromatography using n-hexane-
acetone (6:4) as the mobile phase to yield compound
1 (14 mg).
Spectral analysis for the compound 1 was achieved
by using Jeol-Ex 400 MHz and FT-NMR spectrome-
ters for 1H and 13 C-NMR spectra in CDCL3. The
structure of the compound was confirmed by com-
parison of its spectral data with those published in the
literature [42].
Table 1 Qualitative phytochemical screening of different
extracts from Vanda roxburghii
PEF CLF EAF AQF
Tannins - - - ++
Flavonoids + +++ ++ +
Phenolic compounds + +++ ++ +
Alkaloids - - - +
Saponins - - - ++
Phytosterols ++ + - -
Here, + = Present in mild amount, ++ = Present in moderate amount,
+++ = Present in large amount, − = Absence
PEF petroleum ether fraction, CLF chloroform fraction, EAF ethylacetate
fraction, AQF aqueous fraction
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Table 2 Total phenolic and flavonoid contents and antioxidant activity of different extracts from Vanda roxburghii
Sample TPC TFC DPPH OH FRAP
(mg GAE/g dried extract) (mg CE/g dried extract) IC50 (μg/mL) IC50 (μg/mL) (absorbance at 100 μg/mL)
PEF 23.6 ± 0.21(a) 67.9 ± 1.35(a) 35.02 ± 1.56(d) 23.91 ± 1.58(c) 0.810 ± 0.02(b)
CLF 85.9 ± 1.03(d) 300.1 ± 0.61(d) 5.76 ± 0.42(a) 7.96 ± 0.61(a) 1.397 ± 0.04(d)
EAF 66.7 ± 0.73(c) 164.44 ± 0.85(c) 18.70 ± 0.78(b) 11.13 ± 0.72(a) 1.237 ± 0.04(c)
AQF 36.3 ± 0.60(b) 112.1 ± 0.95(b) 24.86 ± 1.12(c) 15.98 ± 0.86(b) 0.333 ± 0.01(a)
CA - - 4.55 ± 0.33(a) 9.45 ± 0.57(a) 1.48 ± 0.03(e)
Means in each column with different subscript letters (a b, c, d, e) differ significantly (P <0.05)
PEF petroleum ether fraction, CLF chloroform fraction, EAF ethylacetate fraction, AQF aqueous fraction, CA catechin, TPC Total phenolic content, TFC Total flavonoid
content, OH Hydroxyl radical scavenging, FRAP Ferric reducing antioxidant power
Fig. 1 Percentage of inhibition of acetylcholinesterase (a) and butyrylcholinesterase (b) activity at different concentration of V. roxburghii extracts
and the reference standard donepezil or galantamine. Standard was used for comparison. Results represent mean ± SD (n = 3, (P < 0.05). PEF,
petroleum ether fraction; CLF, chloroform fraction; EAF, ethylacetate fraction; AQF, aqueous fraction
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Gigantol (1): colorless gum, UV (in MeOH) λmax, 226 and
282 nm. 1H-NMR (CDCl3): δH 6.81 (1H, d, J = 7.8 Hz), 6.68
(1H, d, J = 7.8 Hz), 6.62 (1H, s), 6.60 (1H, s), 6.24 (1H, s),
6.29 (1H, s), 2.82 (2H, m), 2.79 (2H, m), 3.82 (3H, s) and
3.74 (3H, s). 13C-NMR (CDCl3): δC 160.90 (C-5′), 156.67
(C-3′), 146.30 (C-5″), 144.55 (C-1′), 143.81 (C-4″), 133.64
(C-1″), 121.02 (C-2″), 114.32 (C-3″), 111.21 (C-6″), 108.07
(C-6′), 106.83 (C-4′), 99.06 (C-2′), 55.90 (C5″-OCH3),,
55.27 (C5′-OCH3), 38.29 (C-2), and 37.26 (C-1).
Statistical analysis
All analyses were carried out in triplicates. Data were
presented as mean ± SD. Free R-software version 2.15.1
(http://www.r-project.org/) and Microsoft Excel 2007
(Roselle, IL, USA) were used for the statistical and
graphical evaluations. Significant differences (P-value
<0.05) between the means were determined using the
t-test.
Results and discussion
The practice of traditional medicine has described a
wide range of plants and herbs which may be used in
the treatment of AD. Such plants can play important
roles in providing alternative medicine, adjuncts to existing
therapies, and in the discovery of new pharmacological
compounds. Indeed, one of the most widely used anti-
AD drug, galantamine is derived from the plant [43]. V.
roxburghii, an epiphyte has been used in Unani traditional
medicine as tonic to brain and liver and also used by
the local people of Bangladesh to treat nervous system
disorders [24–26]. In this investigation, we evaluated
the different extracts of V. roxburghii for cholinesterase
inhibitory and antioxidant activities.
Phytochemical analyses
The four different extracts of V. roxburghii viz. petroleum
ether, chloroform, ethylacetate and aqueous extracts were
analyzed qualitatively for the presence or absence of
phytochemicals. The extracts showed the presence of
tannins, phenolics and flavonoids, phytosterols, alkaloids
and saponin (Table 1). Quantitative analyses (Table 2)
revealed that the chloroform extract contained the
highest amount of phenolics and flavonoids followed
by ethylacetate, aqueous and petroleum ether extract.
Cholinesterase inhibitory activity
Because the cholinergic neurotransmitter acetylcholine
is reduced in AD, inhibitor of cholinesterases has been
shown to augment the activity of surviving cholinergic
neurons in patients with AD, resulting in improvement
of memory and cognition. All the cholinesterase inhibitors
currently licensed for AD inhibit acetylcholinesterase and,
to a varying extent, butyrylcholinesterase [11, 12]. The
ability of V. roxburghii to inhibit both AChE and BChE,
was evaluated by the widely accepted modified Ellman’s
method [41] and the results have been shown in the Fig. 1.
All the tested extracts except aqueous extract and
petroleum ether extract inhibited the activity of AChE
and BChE, respectively in a dose dependent manner.
The results revealed that the chloroform extract displayed
the highest inhibitory activity against both the cholinester-
ases, AChE and BChE. The IC50 values of the extract for
AChE and BChE were found to be 221.13 μg/ml and
82.51 μg/ml, respectively, indicating that the chloroform
extract has higher specificity for BChE. The activity of the
chloroform extract was found to be strong when
compared with the other extracts, but moderate when
compared with that of the reference standard donepezil or
Fig. 2 Percentage of lipid peroxidation inhibition at different concentration of V. roxburghii extracts and the reference standard catechin. Standard
was used for comparison. Results represent mean ± SD (n = 3, (P < 0.05). PEF, petroleum ether fraction; CLF, chloroform fraction; EAF, ethylacetate
fraction; AQF, aqueous fraction; CA, catechin
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galantamine, currently used as AD drugs. It has been
reported earlier that dual inhibition of AChE and BChE
might improve the signs of AD and symptoms owing to
the key role of BChE in hydrolysis of acetylcholine [44].
However, our results demonstrated the dual cholinesterase
inhibitory activity of V. roxburghii.
Antioxidant activity
Antioxidant activity of plant extracts cannot be evaluated
by a single method. Therefore, commonly accepted assays
were used to assess the antioxidative effect of the different
extracts of V. roxburghii. In a preliminary study, the
antioxidant activity of the different extractives was
evaluated employing ferric reducing antioxidant power
(FRAP) and DPPH radical scavenging activity. Both
assays demonstrated the potential antioxidant activity of
the chloroform extract which was close to the activity of
the reference standard catechin (Table 2). Chloroform
extract showed the highest activity with an absorbance of
1.39 at 100 μg/ml concentration, which was close to the
activity of the reference standard catechin that gave an
absorbance of 1.48 at the same concentration. In DPPH
radical scavenging, the IC50 of chloroform extract and
catechin was found to be 5.76 and 4.55 μg/ml,
respectively. We then extended our study employing
the assays that are more relevant in vivo. Hydroxyl radicals
Fig. 4 Percentage of DPPH (a) and hydroxyl (OH) radical (b) scavenging activity and lipid peroxidation inhibitory activity (c) at different
concentration of gigantol and the reference standard catechin. Standard was used for comparison. Results represent mean ± SD (n = 3, (P < 0.05)
Fig. 3 Chemical structure of gigantol (a) and its IC50 (mean ± SD) values for DPPH and hydroxyl radical (OH) scavenging and for inhibition of lipid
peroxidation (LPO). * values significantly different (P < 0.05) from the reference standard catechin
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are the major reactive oxygen species that severely damage
the neurons in AD. Our results (Table 2) revealed
that the chloroform extract has potential hydroxyl
radical scavenging activity with an IC50 of 7.96 μg/ml,
which appeared to be more potent than that of the
reference standard catechin used in this study whose
IC50 was found to be 9.45 μg/ml under the same
condition.
Oxidative damage in AD predominantly manifests as
lipid peroxidation and increased lipid peroxidation has
been observed in the brain of AD [14, 45, 46]. Lipid
peroxidation products can be measured by using
thiobarbituric acid [47]. Our results (Fig. 2) showed
that the chloroform extract exhibited the highest activity
among the extracts tested in the inhibition of brain
lipid peroxidation with an IC50 value of 27.52 μg/ml.
Taken together, our results demonstrated the potential
antioxidant activity of the chloroform extract of V.
roxburghii.
Isolation of active compound from the chloroform extract
of V. roxburghii
Since the chloroform extract was found to be the most
active fraction, it was subjected to bioassay-guided
separation using column chromatography and preparative
thin layer chromatography that led to the isolation of a
phenolic component from the active subfraction. The com-
ponent was identified as gigantol by comparing its 1H
NMR and 13C NMR spectra with the literature values [42].
Antioxidant activity of gigantol was again assayed in the
same in vitro system. As shown in Figs. 3 and 4, gigantol
was found to display strong radical scavenging activity
which was consistent with the previous report [32]
and exhibited inhibition of lipid peroxidation in rat
brain homogenates. Both the radical scavenging and
lipid peroxidation inhibitory activities of gigantol were
shown to be dose-dependent. The compound did not
show any activity against the cholinesterases.
Gigantol, a bibenzyle compound has been found to be an
important constituent in the orchid plants and studied for
a number of biological activities. Simmler et al. (2011)
showed that gigantol from V. cerule displayed antioxidant
and anti-inflammatory properties on HaCaT cell by
neutralizing the intracellular ROS and by reducing the ex-
pression of COX-2, thereby reducing PGE-2 production
[32]. In a previous report [48], gigantol from Cymbidium
goeringii has been shown to possess potent inhibitory
effects on LPS-induced nitric oxide (NO) and prostaglandin
E2 (PGE-2) production in RAW 264.7 macrophage cells.
The compound is also reported to reduce carrageenan-
induced inflammation in rats [49]. Several lines of evidence
proposed that inflammation may play a significant role in
the pathogenesis of AD. It has been shown that the depos-
ition of amyloid in AD brain brings about activation of
micriglia and astrocytes, initiating a proinflammatory cas-
cade that results in the release of potentially neurotoxic
substances, cytokines, and other related compounds, bring-
ing about degenerative changes in neurons [50]. Since
gigantol has potential in scavenging free radicals, reducing
lipid peroxidation (our study) and inflammation, suggesting
that it may be a useful candidate drug in the treatment of
AD and thus warrants testing in a animal model.
Conclusions
Results of the present study clearly demonstrated that the
chloroform extract of V. roxburghii, possibly due to its poly-
phenolic compounds, possess a combination of antioxidant
properties and cholinesterase inhibitory activities which
support its traditional utilization in Bangladesh in the treat-
ment of AD. In a reference survey, no reports relating to
the antioxidant and cholinesterase inhibitory activities of V.
roxburghii has extracts have been found so far. Besides
these, gigantol, a bibenzyl stilbenoid was isolated from the
chloroform extract as the potent antioxidant principle.
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